HENNEMAN JOHN B III 4
4 · Anika Therapeutics, Inc. · Filed May 4, 2026
Research Summary
AI-generated summary of this filing
Anika Therapeutics (ANIK) Director John B. Henneman III Buys 5,000 Shares
What Happened
- John B. Henneman III, a director of Anika Therapeutics, acquired 5,000 shares of ANIK in an open-market purchase on 2026-05-01. The filing reports a weighted-average price of $14.66 per share, for a total cost of approximately $73,320. This was a purchase (insider buying).
Key Details
- Transaction date: 2026-05-01; Form 4 filed: 2026-05-04 (filed within required reporting window).
- Reported price: weighted average $14.66; purchases occurred at prices ranging from $14.595 to $14.75 (footnote F1).
- Total shares acquired: 5,000; total value ≈ $73,320.
- Shares owned after the transaction: Not disclosed in this Form 4.
- Notable footnote (F1): The reported price is a weighted average; the purchaser made multiple trades across the $14.595–$14.75 range and will provide a per-price breakdown to the company, shareholders, or SEC staff on request.
Context
- Insider purchases are often watched by investors as a signal that insiders are willing to buy the company’s stock, though they do not guarantee future performance. This filing relates to a director’s open-market purchase (code P), not an option exercise, award, or gift.
Insider Transaction Report
Form 4
HENNEMAN JOHN B III
Director
Transactions
- Purchase
Common Stock
[F1]2026-05-01$14.66/sh+5,000$73,320→ 54,871 total
Footnotes (1)
- [F1]The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.595 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Signature
/s/ John B. Henneman, III|2026-05-04